Iododoxorubicin
Alternative Names: 4-IDX; 4-Iodo-4-deoxydoxorubicin; FCE 21954; I-DOX; Iodo-DoxLatest Information Update: 06 Aug 2002
At a glance
- Originator Pharmacia Corporation
- Class Cytostatic antibiotics
- Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Creutzfeldt-Jakob disease
Most Recent Events
- 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 13 Oct 1998 No-Development-Reported for Alzheimer's disease in Italy (Unknown route)
- 07 Sep 1998 Preclinical development for Creutzfeldt-Jakob disease in Italy (Unknown route)